Cheap Broker Fees
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Regeneron Pharmaceuticals Inc is a biotechnology business based in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars. Regeneron Pharmaceuticals employs 9,635 staff and has a trailing 12-month revenue of around USD$12.2 billion.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Regeneron Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $569.37, which is 29.19% up on its pre-crash value of $403.15 and 67.76% up on the lowest point reached during the March crash when the stocks fell as low as $339.39.
If you had bought $1,000 worth of Regeneron Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $1,335.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,668.25.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$569.37|
|52-week range||$441.00 - $686.62|
|50-day moving average||$620.64|
|200-day moving average||$561.96|
|Wall St. target price||$690.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$55.38|
|1 week (2021-10-14)||2.47%|
|1 month (2021-09-23)||-11.93%|
|3 months (2021-07-23)||-2.90%|
|6 months (2021-04-23)||16.52%|
|1 year (2020-10-23)||-1.80%|
|2 years (2019-10-23)||86.67%|
|3 years (2018-10-23)||49.56%|
|5 years (2016-10-21)||56.62%|
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Regeneron Pharmaceuticals shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0595. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.7 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$12.2 billion|
|Operating margin TTM||52.46%|
|Gross profit TTM||$4.5 billion|
|Return on assets TTM||22.27%|
|Return on equity TTM||51.32%|
|Market capitalisation||$59.2 billion|
TTM: trailing 12 months
There are currently 1.8 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 14.5% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.
Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 711139.13043478). Regeneron Pharmaceuticals's SIR currently stands at 2.53. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 2530 shares are currently held short.
However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0181% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 12/31/2018) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $441 up to $686.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.2132. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.
ProShares Bitcoin Strategy ETF is the first fund tied to the value of a cryptocurrency to trade on the major U.S. markets. Here’s how to invest if you’re in Singapore.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.